Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Study Confirms Association of AD and High Levels of LDL Cholesterol

By LabMedica International staff writers
Posted on 10 Jun 2019
High LDL cholesterol levels have been linked to the risk of developing early-onset Alzheimer's disease (AD).

Early-onset Alzheimer's disease (EOAD), which manifests in individuals younger than age 65, accounts for about 10% of all Alzheimer's cases. In late-onset AD, elevated circulating cholesterol levels increase AD risk even after adjusting for the apolipoprotein E epsilon4 (APOE E4) allele, a major genetic factor for AD and elevated cholesterol levels; however, the role of circulating cholesterol levels in EOAD is unclear.

Investigators at Emory University (Atlanta, GA, USA) studied the association between circulating cholesterol levels and EOAD in order to identify genetic variants underlying this possible association. For this study, the investigators sequenced specific genomic regions of 2,125 subjects, 654 of whom had EOAD and 1,471 controls. They also determined LDL cholesterol levels in blood samples from 267 participants. To determine the underlying genetic variants, APOB, APP, PSEN1, and PSEN2 genes were sequenced in samples from 2125 EOAD cases and controls.

Results revealed that of the 2125 samples that underwent genetic sequencing, 1276 were from women and 654 were from patients with EOAD. APOE E4 explained 10.1% of the variance of EOAD. After controlling for APOE E4, EOAD cases had higher levels of total cholesterol, LDL cholesterol and the LDL protein Apo B than controls in 267 frozen samples. Approximately 3% of EOAD cases carried known AD-causing mutations. Gene-based rare variant burden testing in 2066 samples showed that rare APOB coding variants were significantly more abundant in EOAD cases after adjusting for sex and APOE E4.

The results did not find a link between HDL (high-density lipoprotein) cholesterol levels and EOAD, and only a very slight association between the disease and triglyceride levels.

"The big question is whether there is a causal link between cholesterol levels in the blood and Alzheimer's disease risk," said first author Dr. Thomas Wingo, assistant professor of neurology and human genetics at Emory University. "The existing data have been murky on this point. One interpretation of our current data is that LDL cholesterol does play a causal role. If that is the case, we might need to revise targets for LDL cholesterol to help reduce Alzheimer's risk. Our work now is focused on testing whether there is a causal link."

The study linking EOAD to high LDL cholesterol levels was published in the May 28, 2019, online edition of the journal JAMA Neurology.

Related Links:
Emory University


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
HPV Molecular Controls
ZeptoMetrix® HPV Type 16, 18, 45 & 68 Molecular Controls
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.